Analytics and Assays Strive to Keep Pace with Innovative Modalities

This episode of Drug Digest explores new and emerging technologies, such as mass photometry, machine learning, and AI, and their role in the analytical space for biologic modalities.

Register Free: 
https://www.pharmtech.com/pt_w/innovative-modalities

Event Overview:

With the evolution of biologic modalities in the drug development pipeline, the biopharma industry understands that it must keep pace with the development and use of appropriate analytics and assays for molecule characterization, to determine product purity, safety, and efficacy, and even early on in the R&D process, where analytics are key in screening multitudes of molecules to determine viable candidates to move into the drug development phases. This episode of Drug Digest explores new and emerging technologies, such as mass photometry, machine learning, and AI, and their role in the analytical space for biologic modalities.

Key Learning Objectives:

• Introduction to new/emerging analytical technology: mass photometry
• Discuss unmet needs in biopharma analytics
• Emphasize the new understanding of biological systems from strides in research
• Discover the role digitalization plays in mapping genetic diversity

Who Should Attend:

• R&D
• Lab Analytics personnel
• Investigators
• CROs
  

Speaker:

Salma Jalal
Product Marketing Manager
Refeyn

As a product marketing manager at Refeyn, Salma Jalal supports customers in biopharma and the life sciences to revolutionize their analytical workflows through the use of mass photometry. She holds a PhD in Mechanobiology from the National University of Singapore and has over a decade of technical expertise in the application of microscopy techniques to study biological systems. She has a particular interest in the analysis of biologics and is very happy to discuss all things biomolecular characterization.

Register Free:
https://www.pharmtech.com/pt_w/innovative-modalities